JP2020525435A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525435A5 JP2020525435A5 JP2019570882A JP2019570882A JP2020525435A5 JP 2020525435 A5 JP2020525435 A5 JP 2020525435A5 JP 2019570882 A JP2019570882 A JP 2019570882A JP 2019570882 A JP2019570882 A JP 2019570882A JP 2020525435 A5 JP2020525435 A5 JP 2020525435A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- administration
- dose
- factor according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023067723A JP2023083424A (ja) | 2017-06-21 | 2023-04-18 | 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523182P | 2017-06-21 | 2017-06-21 | |
| US62/523,182 | 2017-06-21 | ||
| PCT/US2018/038798 WO2018237168A1 (en) | 2017-06-21 | 2018-06-21 | Dosing parameters for cd47 targeting therapies to hematologic malignancies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023067723A Division JP2023083424A (ja) | 2017-06-21 | 2023-04-18 | 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020525435A JP2020525435A (ja) | 2020-08-27 |
| JP2020525435A5 true JP2020525435A5 (https=) | 2021-07-29 |
| JP7312706B2 JP7312706B2 (ja) | 2023-07-21 |
Family
ID=64735831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570882A Active JP7312706B2 (ja) | 2017-06-21 | 2018-06-21 | 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ |
| JP2023067723A Pending JP2023083424A (ja) | 2017-06-21 | 2023-04-18 | 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023067723A Pending JP2023083424A (ja) | 2017-06-21 | 2023-04-18 | 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11141480B2 (https=) |
| EP (2) | EP3642242B1 (https=) |
| JP (2) | JP7312706B2 (https=) |
| KR (1) | KR102757177B1 (https=) |
| CN (2) | CN110831974B (https=) |
| AU (2) | AU2018290248B2 (https=) |
| CA (1) | CA3063099A1 (https=) |
| ES (1) | ES2976558T3 (https=) |
| PL (1) | PL3642242T3 (https=) |
| PT (1) | PT3642242T (https=) |
| SI (1) | SI3642242T1 (https=) |
| WO (1) | WO2018237168A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3043181B1 (en) | 2008-01-15 | 2020-04-08 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| ES2582340T3 (es) | 2008-01-15 | 2016-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Métodos para manipular fagocitosis mediada por CD47 |
| US11072655B2 (en) * | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| WO2018237168A1 (en) * | 2017-06-21 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Dosing parameters for cd47 targeting therapies to hematologic malignancies |
| EA202190986A1 (ru) | 2018-11-26 | 2021-12-14 | Фоти Севен, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit |
| US20200400662A1 (en) | 2019-06-07 | 2020-12-24 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| ES2973832T3 (es) * | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| CN121243368A (zh) * | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| CN111905101B (zh) * | 2020-07-03 | 2022-09-23 | 中山大学 | 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其治疗肿瘤的方法 |
| WO2022007947A1 (zh) * | 2020-07-10 | 2022-01-13 | 信达生物制药(苏州)有限公司 | 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途 |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| EP4291216A1 (en) * | 2021-02-09 | 2023-12-20 | University of Houston System | Oncolytic virus for systemic delivery and enhanced anti-tumor activities |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| AU2024225341A1 (en) | 2023-02-21 | 2025-09-04 | Osteal Therapeutics, Inc. | Methods of treating a localized infection with locally administered antibiotics |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2543819T3 (es) | 1998-11-09 | 2015-08-24 | Biogen Inc. | Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20 |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| EP3043181B1 (en) | 2008-01-15 | 2020-04-08 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| ES2582340T3 (es) * | 2008-01-15 | 2016-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Métodos para manipular fagocitosis mediada por CD47 |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| CA2771336C (en) * | 2009-09-15 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| ES2816647T3 (es) | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| NZ710695A (en) * | 2013-02-06 | 2020-05-29 | Inhibrx Inc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| CN112245586A (zh) | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| EP3046627B1 (en) | 2013-09-18 | 2019-10-23 | The Board of Trustees of the Leland Stanford Junior University | Modulation of efferocytosis pathways for treatment of atherosclerotic disease |
| CN103943054B (zh) | 2014-01-27 | 2016-07-13 | 上海中航光电子有限公司 | 栅极驱动电路、tft阵列基板、显示面板及显示装置 |
| KR102271434B1 (ko) | 2014-09-26 | 2021-07-01 | 엘지전자 주식회사 | 이동단말기 및 그 제어방법 |
| CN113528663A (zh) | 2014-12-10 | 2021-10-22 | 得克萨斯州大学系统董事会 | 使用基因组特异性探针的循环肿瘤和肿瘤干细胞检测 |
| WO2017053423A1 (en) * | 2015-09-21 | 2017-03-30 | Erasmus University Medical Center | Anti-cd47 antibodies and methods of use |
| WO2018237168A1 (en) | 2017-06-21 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Dosing parameters for cd47 targeting therapies to hematologic malignancies |
-
2018
- 2018-06-21 WO PCT/US2018/038798 patent/WO2018237168A1/en not_active Ceased
- 2018-06-21 CA CA3063099A patent/CA3063099A1/en active Pending
- 2018-06-21 CN CN201880040266.5A patent/CN110831974B/zh active Active
- 2018-06-21 CN CN202310844109.2A patent/CN117065013A/zh active Pending
- 2018-06-21 EP EP18820011.7A patent/EP3642242B1/en active Active
- 2018-06-21 PL PL18820011.7T patent/PL3642242T3/pl unknown
- 2018-06-21 JP JP2019570882A patent/JP7312706B2/ja active Active
- 2018-06-21 ES ES18820011T patent/ES2976558T3/es active Active
- 2018-06-21 AU AU2018290248A patent/AU2018290248B2/en active Active
- 2018-06-21 EP EP24155725.5A patent/EP4368206A3/en active Pending
- 2018-06-21 PT PT188200117T patent/PT3642242T/pt unknown
- 2018-06-21 SI SI201831075T patent/SI3642242T1/sl unknown
- 2018-06-21 KR KR1020197036583A patent/KR102757177B1/ko active Active
- 2018-06-21 US US16/619,387 patent/US11141480B2/en active Active
-
2021
- 2021-09-07 US US17/468,265 patent/US12274746B2/en active Active
-
2023
- 2023-04-18 JP JP2023067723A patent/JP2023083424A/ja active Pending
- 2023-05-05 US US18/143,978 patent/US12194093B2/en active Active
-
2024
- 2024-10-11 AU AU2024227248A patent/AU2024227248A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020525435A5 (https=) | ||
| Rosenberg et al. | The management of stages I, II, and III Hodgkin's disease with combined radiotherapy and chemotherapy | |
| Kahn et al. | Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. | |
| Zhong et al. | Safety of PD-1/PD-L1 inhibitors combined with palliative radiotherapy and anti-angiogenic therapy in advanced hepatocellular carcinoma | |
| JP2004512262A5 (https=) | ||
| Bowman et al. | Isolated testicular relapse in acute lymphocytic leukemia of childhood: categories and influence on survival. | |
| JP2017537105A5 (https=) | ||
| Rijkmans et al. | Successful treatment of radiation cystitis with hyperbaric oxygen | |
| JP2019508476A5 (https=) | ||
| Sun et al. | Combination with stereotactic body radiotherapy offers a promising strategy to overcome resistance to immunotherapy in advanced renal cell cancer | |
| MX2024014273A (es) | Metodos para eliminar celulas supresoras de origen mieloide con el anticuerpo neo-201 | |
| JP2020517704A (ja) | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 | |
| Abuzakhm et al. | A Phase II Study of Bevacizumab & Temsirolimus in Advanced Extra-Pancreatic Neuroendocrine Tumors | |
| JP2014080429A (ja) | Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療 | |
| Li et al. | Computed tomography-guided iodine-125 radioactive seed implantation in small-cell lung cancer: A retrospective study | |
| Ghalie et al. | Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. | |
| Eden et al. | Testicular irradiation in childhood lymphoblastic leukaemia | |
| Li et al. | Low dose of interferon‑α improves the clinical outcomes of docetaxel in patients with castration‑resistant prostate cancer: A pilot study | |
| Suzuki et al. | Modified TPEx as first-line treatment for recurrent and/or metastatic head and neck cancer | |
| Guerriero et al. | Unusual complication after radiotherapy for breast cancer bronchiolitis obliterans organizing pneumonia case report and review of the literature | |
| Baker et al. | The influence of ICRF‐159 and levamisole on the incidence of metastases following local irradiation of a solid tumor | |
| Choi et al. | Long-term treatment outcomes of children and adolescents with lymphoblastic lymphoma treated with various regimens: a single-center analysis | |
| Vergnenegre et al. | Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer: A phase II trial conducted by the Groupe Français de Pneumo-Cancérologie (GFPC) | |
| US20230226209A1 (en) | Antibody endohedral metallofullerene conjugate and uses thereof | |
| de Choudens et al. | PO13: Bleeding in the Brachytherapy Suite-the Unwanted Surprise |